FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340809549> ?p ?o ?g. }

• W2340809549 endingPage "20527" @default.
• W2340809549 startingPage "20527" @default.
• W2340809549 abstract "20527 Background: Inflammatory or B symptoms are associated with worse treatment response & survival. B symptoms are associated with elevated plasma inflammatory markers including C-reactive protein (CRP), lactate dehydrogenase (LDH) & pro-inflammatory cytokines. The majority of cytotoxic agents are metabolised by the liver. Elevated inflammatory markers have been associated with reduced hepatic drug metabolism. Recent data suggest that cancer associated inflammation reduces hepatic metabolism of cytotoxic drugs leading to increased toxicity. Methods: BNLI compared two chemotherapy regimens (CHOP or PMitCEBO) in 784 older patients with aggressive NHL. Data was reanalysed to compare toxicities & tumour response rates (chi-square & Fisher exact tests), and survival (log-rank test) for patients with & without B symptoms. Results: Patients with B symptoms (54%, n=412) had significantly higher International Prognostic Index scores, disease stage, LDH levels & performance status than those without (p<0.05). Response rate for patients with B symptoms was 87% significantly lower for patients without B symptoms (92%) (OR 1.8, 95% CI: 1.05 - 2.91, p<0.05). After median of 44 months follow-up, the presence of B symptoms resulted in a shorter failure free survival of 1.3 yrs (95% CI: 0.88 - 1.72) vs. 3.6 yrs (95% CI: 1.71 - 5.47, p<0.001), & median overall survival 1.75 yrs (95% CI: 1.27 - 2.23) vs.4.4 yrs (95% CI: 2.89 - 5.91 yrs, p<0.001). Haematological toxicity was significantly worse in patients with B symptoms compared to those without; grades 3–4 leucopenia 57% vs. 40% (p<0.001), anaemia 10% vs. 5% (p<0.001), thrombocytopenia 14% vs. 6% (p<0.001). Grades 3–4 infection occurred in 26% of patients with B symptoms compared to 10% without (p<0.05). Median duration of hospitalisation was 10 days for patients with B symptoms and 5 days for those without (p<0.05). Conclusions: Inflammatory symptoms predict for worse toxicity from chemotherapy in patients with NHL. No significant financial relationships to disclose." @default.
• W2340809549 created "2016-06-24" @default.
• W2340809549 creator A5005708709 @default.
• W2340809549 creator A5012622153 @default.
• W2340809549 creator A5034145053 @default.
• W2340809549 creator A5063111253 @default.
• W2340809549 creator A5064184281 @default.
• W2340809549 creator A5087819197 @default.
• W2340809549 date "2008-05-20" @default.
• W2340809549 modified "2023-10-16" @default.
• W2340809549 title "Use of inflammatory symptoms to predict worse myelosuppression in aggressive non-Hodgkin lymphoma (NHL): Reanalysis of British National Lymphoma Institute (BNLI) study of CHOP versus PMitCEBO with or without granulocyte colony stimulating factor" @default.
• W2340809549 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.20527" @default.
• W2340809549 hasPublicationYear "2008" @default.
• W2340809549 type Work @default.
• W2340809549 sameAs 2340809549 @default.
• W2340809549 citedByCount "0" @default.
• W2340809549 crossrefType "journal-article" @default.
• W2340809549 hasAuthorship W2340809549A5005708709 @default.
• W2340809549 hasAuthorship W2340809549A5012622153 @default.
• W2340809549 hasAuthorship W2340809549A5034145053 @default.
• W2340809549 hasAuthorship W2340809549A5063111253 @default.
• W2340809549 hasAuthorship W2340809549A5064184281 @default.
• W2340809549 hasAuthorship W2340809549A5087819197 @default.
• W2340809549 hasConcept C126322002 @default.
• W2340809549 hasConcept C181199279 @default.
• W2340809549 hasConcept C185592680 @default.
• W2340809549 hasConcept C2777318727 @default.
• W2340809549 hasConcept C2778476033 @default.
• W2340809549 hasConcept C2779338263 @default.
• W2340809549 hasConcept C2779714933 @default.
• W2340809549 hasConcept C2779725641 @default.
• W2340809549 hasConcept C2780653079 @default.
• W2340809549 hasConcept C29730261 @default.
• W2340809549 hasConcept C55493867 @default.
• W2340809549 hasConcept C71924100 @default.
• W2340809549 hasConcept C90924648 @default.
• W2340809549 hasConceptScore W2340809549C126322002 @default.
• W2340809549 hasConceptScore W2340809549C181199279 @default.
• W2340809549 hasConceptScore W2340809549C185592680 @default.
• W2340809549 hasConceptScore W2340809549C2777318727 @default.
• W2340809549 hasConceptScore W2340809549C2778476033 @default.
• W2340809549 hasConceptScore W2340809549C2779338263 @default.
• W2340809549 hasConceptScore W2340809549C2779714933 @default.
• W2340809549 hasConceptScore W2340809549C2779725641 @default.
• W2340809549 hasConceptScore W2340809549C2780653079 @default.
• W2340809549 hasConceptScore W2340809549C29730261 @default.
• W2340809549 hasConceptScore W2340809549C55493867 @default.
• W2340809549 hasConceptScore W2340809549C71924100 @default.
• W2340809549 hasConceptScore W2340809549C90924648 @default.
• W2340809549 hasIssue "15_suppl" @default.
• W2340809549 hasLocation W23408095491 @default.
• W2340809549 hasOpenAccess W2340809549 @default.
• W2340809549 hasPrimaryLocation W23408095491 @default.
• W2340809549 hasRelatedWork W1898697707 @default.
• W2340809549 hasRelatedWork W1983309704 @default.
• W2340809549 hasRelatedWork W1996808463 @default.
• W2340809549 hasRelatedWork W2018368873 @default.
• W2340809549 hasRelatedWork W2158020131 @default.
• W2340809549 hasRelatedWork W2292265136 @default.
• W2340809549 hasRelatedWork W2899250601 @default.
• W2340809549 hasRelatedWork W2993375378 @default.
• W2340809549 hasRelatedWork W2995560577 @default.
• W2340809549 hasRelatedWork W79716904 @default.
• W2340809549 hasVolume "26" @default.
• W2340809549 isParatext "false" @default.
• W2340809549 isRetracted "false" @default.
• W2340809549 magId "2340809549" @default.
• W2340809549 workType "article" @default.